Financial PerformanceThe company reported 2Q24 total revenue of $186.7M, above analyst estimates of $156.2M and consensus of $178.3M.
Pipeline PotentialSepiapterin for PKU is seen as the most notable opportunity for PTCT, with a large opportunity due to the number of PKU patients not well-controlled on existing treatments.
Regulatory DevelopmentsPTCT is preparing to meet with the FDA to discuss the potential for accelerated approval for PTC518 in Huntington's disease (HD).